Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acceleron Pharma, Inc.

http://acceleronpharma.com/

Latest From Acceleron Pharma, Inc.

Merck & Co. Heads Into A Year Of Portfolio Expansion

The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.

Sales & Earnings Launches

How To Improve ClinicalTrials.gov Reporting? Have Centralized Unit Oversee Tasks

Report by Clinical Trials Transformation Initiative identifies barriers to registration and reporting of clinical trial results to ClinicalTrials.gov and the need for centralized approach to monitor process and educate those responsible for submitting information to the site.

Clinical Trials FDA

Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon

Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.

Deal Watch Business Strategies

Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter

Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register